{"id":"W2948405934","doi":"10.1200/jco.19.00882","title":"Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":248,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Cancer Institute; American Society of Clinical Oncology","keywords":"Pertuzumab; Medicine; Trastuzumab emtansine; Internal medicine; Hazard ratio; Trastuzumab; Oncology; Breast cancer; Docetaxel; Adverse effect; Cancer; Surgery; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003426176,0.0002881139,0.002593564,0.000157617,0.00009529421,0.00003010936,0.0004017806,0.0003314684,0.002792862],"category_scores_gemma":[0.002354202,0.0001661288,0.000360578,0.0002320464,0.0003952222,0.0001638598,0.0001707346,0.002491365,0.00002720403],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007087806,"about_ca_system_score_gemma":0.002322847,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002956511,"about_ca_topic_score_gemma":0.0031674,"domain_scores_codex":[0.9942998,0.001146241,0.002755967,0.0004515611,0.0008649754,0.0004815139],"domain_scores_gemma":[0.9911066,0.006241063,0.001151577,0.0003616072,0.0006350722,0.0005040332],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.009358034,0.004553228,0.8904425,0.00002162939,0.0006607369,0.0007737456,0.001058168,0.000001972256,0.0004905828,0.00002014131,0.00215957,0.09045967],"study_design_scores_gemma":[0.04718569,0.01901218,0.9301007,0.000221659,0.0002506569,0.0001361813,0.001363777,0.00008005986,0.00003176516,0.00007322067,0.00138652,0.0001576362],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9634323,0.0004641885,0.00001958904,0.03340045,0.001040608,0.001081827,0.0001749524,0.00001132262,0.0003747841],"genre_scores_gemma":[0.9958166,0.0005235019,0.0002036359,0.001643895,0.001567563,0.00001644173,0.00000855366,0.00004088661,0.0001789339],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09030204,"threshold_uncertainty_score":0.9998099,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1404453096150034,"score_gpt":0.5111550693327782,"score_spread":0.3707097597177748,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}